Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

This US guidance is based on evidence from 41 articles. Recommendations are given on treatment of triple-negative breast cancer, hormone receptor-positive and HER2-negative tumours, and HER2-positive disease.

Journal of Clinical Oncology